Related references
Note: Only part of the references are listed.HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape
Francisco Perea et al.
ONCOTARGET (2018)
Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients
Xiaofang Xing et al.
ONCOIMMUNOLOGY (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung
Ayako Hirai et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2018)
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Benjamin Herzberg et al.
ONCOLOGIST (2017)
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
Michal Smahel
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung
Tomoyuki Igarashi et al.
ONCOLOGY REPORTS (2017)
Targeting the PD-1 pathway: a new hope for gastrointestinal cancers
Burak Bilgin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
Francesco Sabbatino et al.
CLINICAL CANCER RESEARCH (2016)
Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection
Shohei Eto et al.
GASTRIC CANCER (2016)
Programmed Death Ligand-1 Immunohistochemistry Friend or Foe?
Keith M. Kerr et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Lucia Festino et al.
DRUGS (2016)
Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition
Barbara Melosky et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?
Marco Puzzoni et al.
TARGETED ONCOLOGY (2016)
Targeted therapies in gastric cancer and future perspectives
Ozan Yazici et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma
Walid L. Shaib et al.
JOURNAL OF CLINICAL MEDICINE (2016)
Immune targeting of cancer stem cells in gastrointestinal oncology
Robert J. Canter et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2016)
The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1
Zhaohui Jin et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2016)
PD-L1 testing, fit for routine evaluation? From a pathologist's point of view
Georg Hutarew
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
PD-1 and PD-L1 blockade in gastrointestinal malignancies
Hazel Lote et al.
CANCER TREATMENT REVIEWS (2015)
PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises
F. Massari et al.
CANCER TREATMENT REVIEWS (2015)
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Xiangjiao Meng et al.
CANCER TREATMENT REVIEWS (2015)
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Kathleen M. Mahoney et al.
CLINICAL THERAPEUTICS (2015)
Programmed death-1 checkpoint blockade in acute myeloid leukemia
Alison Sehgal et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer
Edward B. Garon
SEMINARS IN ONCOLOGY (2015)
Nuclear Factor Kappa B, Matrix Metalloproteinase-1, p53, and Ki-67 Expressions in the Primary Tumors and the Lymph Node Metastases of Colorectal Cancer Cases
Ibrahim Meteoglu et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy
Yuichiroh Umemoto et al.
JOURNAL OF GASTROENTEROLOGY (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer
Raoul A. Droeser et al.
EUROPEAN JOURNAL OF CANCER (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance
Changping Wu et al.
ACTA HISTOCHEMICA (2006)
Biological characteristics of breast cancer at the primary tumour and the involved lymph nodes
E Dikicioglu et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2005)
Share Paper
